Article
Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.
Infection and immunity - 1 Sept 2005
Smith T J, Lou J, Geren I N, Forsyth C M, Tsai R, Laporte S L, Tepp W H, Bradshaw M, Johnson E A, Smith L A, Marks J D
Abstract excerpt
The botulinum neurotoxins (BoNTs) are category A biothreat agents which have been the focus of intensive efforts to develop vaccines and antibody-based prophylaxis and treatment. Such approaches must take into account the extensive BoNT sequence variability; the seven BoNT serotypes differ by up...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.